Celldex Therapeutics buy Guggenheim
Start price
27.02.24
/
50%
€47.20
Target price
27.02.25
€82.92
Performance (%)
-59.11%
End price
28.02.25
€19.30
Summary
This prediction ended on 28.02.25 with a price of €19.30. Massive losses of -59.11% were the result for the BUY prediction by Guggenheim. Guggenheim has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Celldex Therapeutics | -4.762% | -4.762% | -5.512% |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% |
Comments by Guggenheim for this prediction
In the thread Celldex Therapeutics diskutieren
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target raised by analysts at Guggenheim from $72.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for CLDX provided by MarketBeat
In the thread Trading Celldex Therapeutics
Die von Guggenheim gewählte maximale Laufzeit wurde überschritten